Cadila Healthcare Limited
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- ₹624.15
- Today's High:
- ₹642.85
- Open Price:
- ₹626.45
- 52W Low:
- ₹347.0655
- 52W High:
- ₹668.5
- Prev. Close:
- ₹628.7
- Volume:
- 70941
Company Statistics
- Market Cap.:
- ₹438.16 billion
- Book Value:
- 114.715
- Revenue TTM:
- ₹148.50 billion
- Operating Margin TTM:
- 16.66%
- Gross Profit TTM:
- ₹91.73 billion
- Profit Margin:
- 11.4%
- Return on Assets TTM:
- 6.5%
- Return on Equity TTM:
- 13.54%
Company Profile
Cadila Healthcare Limited had its IPO on under the ticker symbol 532321.
The company operates in the Other sector and Other industry. Cadila Healthcare Limited has a staff strength of 25,000 employees.
Stock update
Shares of Cadila Healthcare Limited opened at ₹626.45 at the start of the last trading session i.e. 2023-09-13.
The stocks traded within a range of ₹624.15 - ₹642.85, and closed at ₹627.65.
This is a -0.17% slip from the previous day's closing price.
A total volume of 70,941 shares were traded at the close of the day’s session.
In the last one week, shares of Cadila Healthcare Limited have increased by +1.14%.
Cadila Healthcare Limited's Key Ratios
Cadila Healthcare Limited has a market cap of ₹438.16 billion, indicating a price to book ratio of 3.711 and a price to sales ratio of 2.9817.
In the last 12-months Cadila Healthcare Limited’s revenue was ₹148.50 billion with a gross profit of ₹91.73 billion and an EBITDA of ₹31.45 billion. The EBITDA ratio measures Cadila Healthcare Limited's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Cadila Healthcare Limited’s operating margin was 16.66% while its return on assets stood at 6.5% with a return of equity of 13.54%.
In Q3, Cadila Healthcare Limited’s quarterly earnings growth was a positive 340% while revenue growth was a positive 13.5%.
Cadila Healthcare Limited’s PE and PEG Ratio
- Forward PE
- 23.2558
- Trailing PE
- 25.7618
- PEG
Its diluted EPS in the last 12-months stands at ₹16.546 per share while it has a forward price to earnings multiple of 23.2558 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Cadila Healthcare Limited’s profitability.
Cadila Healthcare Limited stock is trading at a EV to sales ratio of 3.1881 and a EV to EBITDA ratio of 15.1701. Its price to sales ratio in the trailing 12-months stood at 2.9817.
Cadila Healthcare Limited stock pays annual dividends of ₹7 per share, indicating a yield of 1.64% and a payout ratio of 21.16%.
Balance sheet and cash flow metrics
- Total Assets
- ₹274.71 billion
- Total Liabilities
- ₹83.66 billion
- Operating Cash Flow
- ₹18.12 billion
- Capital Expenditure
- ₹6.06 billion
- Dividend Payout Ratio
- 21.16%
Cadila Healthcare Limited ended 2024 with ₹274.71 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹274.71 billion while shareholder equity stood at ₹161.88 billion.
Cadila Healthcare Limited ended 2024 with ₹0 in deferred long-term liabilities, ₹83.66 billion in other current liabilities, 1024000000.00 in common stock, ₹160.86 billion in retained earnings and ₹53.53 billion in goodwill. Its cash balance stood at ₹3.75 billion and cash and short-term investments were ₹44.55 billion. The company’s total short-term debt was ₹42,069,000,000 while long-term debt stood at ₹4.46 billion.
Cadila Healthcare Limited’s total current assets stands at ₹123.98 billion while long-term investments were ₹0 and short-term investments were ₹38.09 billion. Its net receivables were ₹32.32 billion compared to accounts payable of ₹0 and inventory worth ₹35.19 billion.
In 2024, Cadila Healthcare Limited's operating cash flow was ₹18.12 billion while its capital expenditure stood at ₹6.06 billion.
Comparatively, Cadila Healthcare Limited paid ₹0.21 in dividends in 2024.
Other key metrics
- Current Trading Price
- ₹627.65
- 52-Week High
- ₹668.5
- 52-Week Low
- ₹347.0655
- Analyst Target Price
- ₹
Cadila Healthcare Limited stock is currently trading at ₹627.65 per share. It touched a 52-week high of ₹668.5 and a 52-week low of ₹668.5. Analysts tracking the stock have a 12-month average target price of ₹.
Its 50-day moving average was ₹623.56 and 200-day moving average was ₹509.52 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 7500% of the company’s stock are held by insiders while 1231.5% are held by institutions.
Frequently Asked Questions About Cadila Healthcare Limited
Similar Industry Stocks (Other)
Most Active
Top Gainers
Top Losers
About
Cadila Healthcare Limited engages in the research, development, production, marketing, and distribution of pharmaceutical products in India, the United States, and internationally. It offers finished dosage human formulations comprising generics, branded generics, and specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; animal healthcare products; and consumer wellness products. The company offers products in the therapeutic areas of pain management, neurology, dermatology, rare diseases, specialty oncology, gastroenterology, and liver diseases. It also provides consumer wellness products, such as Sugar Free and Sugarlite; Complan; EverYuth, a range of skincare products; Nycil, a prickly heat powder; Glucon-D glucose powder; Sampriti Ghee; Nutralite; and various other products. In addition, the company is developing drugs in the areas of oncology, autoimmune disease, nephrology, ophthalmology, inflammation, rheumatology, hepatology, infectious disease, etc. Further, it offers animal healthcare products for various therapeutic areas, such as anti-bacterial, NSAIDs, anti-mastitis, tonics, and poultry vaccines. The company also engages in the retail pharmacy, and manpower supply and administration activities. Cadila Healthcare Limited was founded in 1952 and is based in Ahmedabad, India.